Member Info for RMFatGB

- AVA6000 uses Dox.

- Dox is not suitable for all cancer types.

- There are other toxins suitable for other cancer type but they are too toxic.

- Deliver these other toxins with pre|CISION.

- That’s the pipeline being worked on in parallel.

- More news later in the year, the reveal

Short Selling:

Because of the General Election, the closing date for the Short Selling Petition has changed. All petitions now have to close at 00:01am on 30 May. This is because Parliament will be dissolved, which means all parliamentary business – including petitions – must stop. This means the petitions site will be closed and people will not be able to start or sign petitions.

Don't forget

https://avacta.com/precision-adc/

The Avacta pre|CISION-ADC platform leverages the FAP-activated tumour-specific release mechanism of the pre|CISIONTM technology with the tumour-targeting capability of an antibody or Affimer®.

The mechanism of action of the pre|CISION-ADC model optimises warhead delivery by targeting the warhead to the TME in two ways: with the antibody or Affimer® target and FAP-release in the TME.

Optimisation of the bystander effect is a key benefit of the mechanism of the pre|CISION-ADC platform. The biologic targets the molecule to the TME through a non-internalising mechanism and membrane-bound FAP releases the warhead in the extracellular space, thus equally targeting both antigen-positive and antigen-negative tumour cells.

The dual-delivery by a pre|CISION-ADC drug leveraging both a tumour antigen to target and FAP to release the warhead will significantly reduce the off-tumour toxicities associated with traditional ADC mechanisms.

DB Target price is currently under internal investigation.

So, even with this weeks RNS, it would appear that we require deals (income) to push the share price in a positive direction.

The RNS confirmed that Phase 1, Cohorts 1 to 7, is now complete. The Cohort 7 dosing was 385 mg/m2, (3.5x the standard dose) and, if given straight, it could prove fatal. Avacta has improved delivery and safety.

2 weekly dosing is ongoing in the USA and Avacta now have permission to start an additional 2 week trial in the UK. Hopefully to improve efficacy and outcomes.

Avacta presents at AACR on Tuesday 9th April. We know the above, however, we do not have the latest numbers relating to signs of efficacy or patient condition, (improvement). If we do not know, the general market and, possibly, Big Pharma (BP) don’t know.

We do not expect much share movement until AACR. Personally, I am expecting that data presented at AACR to be extremely positive and this will encourage BP to proceed with deals or even a possible buy-out. We may, subject to the quality of the data, witness the start of a bidding war.

As last night’s news confirmed, it doesn’t matter who you are, how old you are or how much money you may have, cancer can strike any of us at any time. If we do have the new standard of care, (treatment), we need to bring this to market as soon as possible and this will require more resources than Avacta currently has.

Wishing King Charles, Princess Katherine and all other cancer suffers a kind and caring treatment with positive outcomes.

Avacta is keeping the data very private for maximum impact at AACR. We are all waiting the reveal with the possible opportunities and outcomes to follow.

GLA

Avacta currently has 284m shares outstanding and a market cap at £150m.

Avacta has cash in the bank but not sufficient to take AVA6000 all the way. Avacta required additional funds via a licencing agreement, an acquisition or, as we now know, a fund raise.

The fund raise will be approved on Monday and Avacta will have additional funds in the bank. The dilution will reduce the value of existing shares by around 25% so long term holders will, understandably, fell aggrieved. With 350m shares outstanding, and a share price at £0.50, the market cap will sit at £175m.

AS has stated for some time that it is important to hold scientific information (data) back to ensure the most impact at the Big Reveal. Avacta will start to make the Big Reveal on Tuesday 9th April while presenting at the AACR in San Diego. We may see an RNS(s) before then.

Avacta now has:

- An innovative platform (pre|CISIONTM) which presents multiple opportunities and applications.

- A tumour activated form of doxorubicin (AVA6000). The new standard, (Dr William Tap)?

- Months of impressive data from the AVA6000 Phase 1a clinical study, (started Aug 2021).

- Cash in the bank, (> £50m) after the fund raise.

- Other innovative science such as Affimer® technology.

- A profitable Diagnostics business.

For me, the above has a value considerably higher than £175m. There will be discussions with Big Pharma and there will be interest in both AVA6000 and the pre|CISIONTM platform. Frustrated as many are, myself included, it’s a waiting game.

Waiting to see what the next few weeks and months may bring.

GLA

But you didn’t answer the question. Would love to hear your ideas. Please try again before the end of the day. Would hate to put you in the green bin.

@ GeneralOz

You have some definite ideas and opinions on what and who is failing. Why did you wait so long to express these concerns? If only you had created your account before 26th Feb 2024.

@LovableLumax

Any candidates to replace the current management team?

If they are really good, when can they start?

If the Avacta data was good in September 2022, imagine what it is like now, ..

05 Sep 2022

https://avacta.com/ava6000-receives-orphan-drug-designation-from-the-us-food-and-drug-administration/

AVA6000 receives Orphan Drug Designation from the US Food and Drug Administration

Avacta announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.

Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:

“We are delighted to receive Orphan Drug Designation from the FDA for AVA6000, which is a reflection of the high quality of the preclinical data and the potential benefit the pre|CISION platform can bring to cancer patients”.

GLA

BP spend US$ Billions each year on R&D. In 2023, spending in the pharmaceutical industry totalled 244 billion U.S. dollars globally.

Roche, Celgene, Bristol-Myers, John & Johnson, Pfizer, Astra Zeneca, Merck, Novartis and Abbvie all spend tens of billions each year and it is not all with success.

If Big Pharma were to acquire Avacta, they get a very experienced team along with the innovative pre|CISION™ platform and the novel Affimer® biotherapeutics platform.

Avacta gets the financial reserves and resources to bring these life-saving platforms to the global health market and achieve a paradigm shift in how chemotherapy is delivered to cancer patients.

BP, Avacta, patients and shareholders all win.

GLA

Avacta, a Novartis Company, that would be an interesting RNS, ..

Good spot by RAH.

AVA6000 now has 3 investigators at the Memorial Sloan Kettering Cancer Center in NY, https://www.mskcc.org/cancer-care/clinical-trials/22-428

Dr. William Tap and his Co-Investigators (Sujana Movva & Alan Ho) must be doing something. Perhaps there is so much to do, and so much data to review, they need 3 investigators to manage and document it all?

Not much news but things are being done!

GLA

Will bem oving - will be moving

It’s all very encouraging and there are discussions in place with both the medical world and big pharma. We will bem oving forward with the Phase 2 study, licensing deals and more. Sit tight, ..

13th Dec 2023 RNS

https://avacta.com/als-6000-101-phase-1a-three-weekly-dose-escalation-safety-study-data/

The key conclusions drawn from the data for AVA6000 to date are:

- The pre|CISIONTM platform targets the release of a chemotherapy to the tumour as intended.

- AVA6000 has significantly improved the safety and tolerability of doxorubicin.

- AVA6000 has shown encouraging preliminary clinical signs of anti-tumour activity.

- The next steps with AVA6000 involve optimising the patient population, dose and schedule in order to increase efficacy and tolerability of doxorubicin treatment via pre|CISIONTM.

Given the favourable safety data from the three-weekly dosing study, a fortnightly dosing study, which is now screening patients with high FAP levels in the United States, will assist in optimising the schedule and dose for a potentially pivotal Phase 2 study in 2024.

Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:

“The encouraging safety and tolerability observed with the pre|CISION™ platform facilitates optimisation of dosing used with existing chemotherapies by exploring higher and more frequent doses and/or more treatment cycles. The ability to target the activation of a toxic drug to the tumour tissue also makes it possible to consider using even more potent cytotoxics that could not previously have been administered as systemic chemotherapies for safety reasons.

“The potential of the pre|CISIONTM platform to change the way in which potent cytotoxic drugs are delivered, improving cancer patients’ quality of life and treatment outcomes, is truly remarkable.”

Dr William Tap, Chief, Sarcoma Medical Oncology at Memorial Sloan Kettering Cancer Center, NY also commented:

“These initial clinical data are encouraging and demonstrate that the novel drug delivery mechanism of AVA6000 has the potential to demonstrate single agent activity in patients with solid tumours that express high levels of FAP. The safety data when compared with standard doxorubicin are highly encouraging and demonstrate the power of the pre|CISION™ platform to avoid normal tissue effects while concentrating the toxin in the tumour microenvironment.”

GLA

Interesting, (curious), wait to see.

Thank you

Hello ES

Value your contributions. Not a big Twiitter (X) user. Care to expand on this?

Hello Bella

I was hoping for more of a licence agreement with upfront payment.

If the next RNS is " Qrtly repayment/share issue", might also include something on funding?

If not, perhaps waiting the next few RNS(s)

In addition to Avacta, I also hold shares in Horsham based Ceres Power.

Ceres released an RNS this morning stating “Ceres and Delta have signed a global long-term manufacturing collaboration and licence agreement”. The share price is up 45% and that’s how quickly things can change.

See: https://www.ceres.tech/category/news/

Waiting the next RNS from Avacta with anticipation.

GLA👍

Good recall ES

There were over 1600 attendees on the AVA6000 review on 13th December 2023. How many of these will be at the JP Morgan conference this month? Major deals can be struck when least expected.